Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is ...

The device gained approval in the US in 2019 and received CE marking for use in the EU in 2014.

CVRx, Inc. initiates landmark BENEFIT-HF trial with FDA-approved Barostim device, aiming to expand heart failure patient ...

CVRx, Inc. a developer of neuromodulation solutions for patients with cardiovascular diseases, announced initiation of the ...

Investing.com -- CVRx Inc. (NASDAQ:CVRX) stock rose 2.9% in after-hours trading Thursday following the company’s announcement ...

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and ...

Chuck Moon, a congestive heart failure patient, experienced significant improvement in his quality of life after receiving a Barostim device implant. The Barostim device is a new technology that acts ...

CVRx, Inc. announced at the Technology and Heart Failure Therapeutics (THT) conference that new real-world evidence demonstrates significant reductions in hospital visits and length of stay after ...

CMS proposed to retain Barostim implant procedure in APC 1580 with a $45,000 outpatient payment, enhancing reimbursement for heart failure treatments. CVRx, Inc. announced that the Centers for ...

MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRX) (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services ...

A new device called Barostim is helping heart failure patients at Christ Hospital in Cincinnati live more normal lives without major surgery, as experienced by local grandfather Eric Townsend.For ...

TUCSON, Ariz. (KVOA) - Carondelet St. Mary's Hospital has successfully completed its first implantation of the Barostim™ Baroreflex Activation Therapy device, marking a significant advancement in the ...